US 12,465,563 B2
Botulinum toxin formulations and methods for intranasal delivery thereof for the treatment of allergic rhinitis
Francesco Barbagallo, Hawthorn (AU)
Appl. No. 17/757,116
Filed by Francesco Barbagallo, Hawthorn (AU)
PCT Filed Dec. 13, 2020, PCT No. PCT/AU2020/051364
§ 371(c)(1), (2) Date Jun. 9, 2022,
PCT Pub. No. WO2021/113926, PCT Pub. Date Jun. 17, 2021.
Claims priority of application No. 2019904728 (AU), filed on Dec. 13, 2019.
Prior Publication US 2023/0000761 A1, Jan. 5, 2023
Int. Cl. A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 31/167 (2006.01); A61K 38/48 (2006.01); A61M 31/00 (2006.01)
CPC A61K 9/0043 (2013.01) [A61K 31/137 (2013.01); A61K 31/167 (2013.01); A61K 38/4893 (2013.01); A61M 31/00 (2013.01); C12Y 304/24069 (2013.01); A61M 2202/049 (2013.01); A61M 2210/0681 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A method for intranasal delivery of a formulation comprising Botulinum toxin for the treatment of allergic rhinitis, the method comprising:
impregnating an exterior of an absorbent tip of an applicator with the formulation prior to insertion of the applicator into a nasal cavity, the applicator comprising a rigid rod having the absorbent tip at a distal end thereof;
initially targeting the nasal cavity by using the applicator to target inside a nasal vestibule, septal walls and a dorsal roof of the nasal cavity, wherein the initial targeting is performed from 2 minutes to 8 minutes;
inserting the applicator straight into the nasal cavity of a patient beneath the lower turbinates to target the nasal- or nasopharynx-associated lymphoid tissue (NALT) and the eustachian tube opening zone of the nasopharynx within the nasal cavity with the absorbent tip; and
massaging the absorbent tip back-and-forth across the NALT and the eustachian tube opening zone, wherein the NALT and the eustachian tube opening zone are targeted for more than 10 minutes.